Biogen/ US09062X1037 /
2024-04-19 9:59:52 PM | Chg. +3.92 | Volume | Bid10:25:00 PM | Ask10:25:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
194.42USD | +2.06% | 76,303 Turnover: 6.47 mill. |
-Bid Size: - | -Ask Size: - | 28.26 bill.USD | - | 24.24 |
GlobeNewswire
03-13
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
GlobeNewswire
03-11
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...
GlobeNewswire
03-08
From the Beach to the Boardroom: Unispace's 'Art for Impact' Program Partners with NGO to Turn 50,00...
GlobeNewswire
03-07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BI...
GlobeNewswire
03-06
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-28
Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study
GlobeNewswire
02-27
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...
GlobeNewswire
02-24
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockhold...
GlobeNewswire
02-23
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
GlobeNewswire
02-22
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, A...
GlobeNewswire
02-22
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business High...